Cancer chemo-immunotherapy: time will tell

Earlier time-of-day administration of chemo-immunotherapy nearly doubled progression-free survival in patients with non-small cell lung cancer.

• Endogenous circadian programs influence immune cell behavior and drug metabolism.
• Previous studies indicated that the timing of immune checkpoint inhibitor delivery might affect cancer survival rates.
• The LungTIME-C01 trial demonstrated that administering treatment before 3pm significantly improved patient outcomes.
• The observed benefits may be linked to factors such as circadian immune regulation and drug effects rather than timing alone.
• Future trials may need to separate the timing effects of immunotherapy from those of chemotherapy for clearer insights.

AI simplified